Area of research
Immunology · Oncology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, and Sarcoma Diagnosis and Treatment.
Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation
Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox.
Phase I/II trial of BMS-986,205 and nivolumab as first line therapy in hepatocellular carcinoma.
Radiotherapy Combined with Intralesional Immunostimulatory Agents for Soft Tissue Sarcomas.
Visceral fat area and subcutaneous fat area as measures of body composition in soft tissue sarcoma.
Scrutinizing the use of contrasted chest CTs in extremity sarcoma staging and surveillance.
Low-Dose Sorafenib Promotes Cancer Stem Cell Expansion and Accelerated Tumor Progression in Soft Tissue Sarcomas.
Post-death Vesicles of Senescent Bone Marrow Mesenchymal Stromal Polyploids Promote Macrophage Aging and Breast Cancer
Multifaceted effects of obesity on cancer immunotherapies: Bridging preclinical models and clinical data.
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial.
Regulation of human and mouse bystander T cell activation responses by PD-1
Advances in Radiotherapy Immune Modulation: From Bench-to-Bedside and Back Again.
Fatty acid oxidation fuels glioblastoma radioresistance with CD47-mediated immune evasion
Aging augments obesity-induced thymic involution and peripheral T cell exhaustion altering the "obesity paradox".
Intralesional interleukin‐2 augmentation therapy in treatment‐refractory melanoma
Intralesional interleukin-2 augmentation therapy in treatment-refractory melanoma.
Head and Neck Cutaneous Soft-Tissue Sarcoma Demonstrate Sex and Racial/Ethnic Disparities in Incidence and Socioeconomic Disparities in Survival.
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-Dose or Hypofractionated Radiation for Patients with Metastatic Colorectal Cancer
Mechanisms by Which Obesity Promotes Acute Graft-<i>Versus</i>-Host Disease in Mice.
T Cell Immune Profiles of Blood and Tumor in Dogs Diagnosed With Malignant Melanoma.
Mouse Preclinical Cancer Immunotherapy Modeling Involving Anti-PD-1 Therapies Reveals the Need to Use Mouse Reagents to Mirror Clinical Paradigms.
Parallels Between the Antiviral State and the Irradiated State.
Surgical and oncologic outcomes following arterial resection and reconstruction for advanced solid tumors.
An Analysis of Daily Setup Variation in Prone Breast Radiation of Early-Stage Breast Cancer.
Dual blockade of CD47 and HER2 eliminates radioresistant breast cancer cells
Effects of Radiation on the Tumor Microenvironment.
Neoadjuvant Immunotherapy-Based Systemic Treatment in MMR-Deficient or MSI-High Rectal Cancer: Case Series.
MRI Radiomics for Prediction of Tumor Response and Downstaging in Rectal Cancer Patients after Preoperative Chemoradiation.